Benign Prostatic Hyperplasia
Finasteride is the preferred 1st line 5α-reductase inhibitor for Benign Prostatic Hyperplasia (BPH) within the Lancashire ad South Cumbria Health Economies. This is because:
Finasteride is significantly less expensive than the alternative 5‑α reductase inhibitor dutasteride.
The Enlarged Prostate International Comparator Study (EPICS) found, when dutasteride or finasteride were administered for 12 months, they were similarly effective at 3 months and 12 months in reducing prostate volume, improving Qmax and urinary symptoms associated with BPH.
Additionally the EPICS study also found no difference in overall numbers of adverse events between finasteride and dutasteride.
Reason for decision:
Suitable for initiation in primary care